Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Somerset's Midwives Can Now Offer Women A New Early Pregnancy Support Service, UK
Women in Somerset now have a new of expert information and advice available to them as soon as they know they are pregnant.
generic viagra online
Arrayit Corporation Addresses Flu Pandemic
Arrayit Corporation (OTCBB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced that its microarray-based diagnostic test, patented under the trade name Variation Identification Platform (VIP), is ready for manufacture and distribution. A breakthrough screening test using VIP will allow clinicians and researchers to test and detect the H1N1 swine flu virus in population wide studies.
News of the day
Boys With Intermittent Eye Deviation Appear More Likely To Develop Mental Illness
Children and especially boys diagnosed with intermittent exotropia, a condition in which the eye turns outward (away from the nose) only some of the time, appear more likely to develop mental illness by young adulthood than children without strabismus (when the eyes deviate or are misaligned when looking at an object), according to a report in the June issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Sexual Health

First-Line Nab-Paclitaxel Is Superior To Docetaxel For Metastatic Breast Cancer

CHICAGO, May 26, 2009 - New data show that nab-paclitaxel (AbraxaneR for Injectable Suspension) prolongs investigator-assessed, median progression-free survival (PFS) by almost seven months versus the highest standard dose of docetaxel in women with metastatic breast cancer. Nab-paclitaxel is a novel albumin-bound paclitaxel, an established chemotherapy agent, combined with albumin, a very small naturally-occurring protein. The findings, from a phase 2 trial that enrolled 302 women with previously untreated metastatic breast cancer, were published online today in the Journal of Clinical Oncology (JCO). "We believe that the results suggest that weekly nab-paclitaxel may be a suitable alternative to the taxane docetaxel given every three weeks for the first-line treatment of metastastic breast cancer," principal investigator William J. Gradishar, MD, Director of Breast Medical Oncology at Northwestern University"s Robert H. Lurie Comprehensive Cancer Center, said. In prior research involving metastatic breast cancer patients, nab-paclitaxel had produced significantly higher anti-tumor activity than solvent-based paclitaxel. The present study was undertaken to evaluate the efficacy and safety of three nab-paclitaxel dosing regimens (weekly versus every three weeks) and to examine differences in safety and efficacy between these dosing regimens of nab-paclitaxel and docetaxel administered at the highest standard dose. Patients were randomized to receive nab-paclitaxel 300 mg/m2 every three weeks (q3w), 100 mg/m2 weekly, 150 mg/m2 weekly, or docetaxel 100 mg/m2 q3w. Results showed that patients treated with nab-paclitaxel 150 mg/m2 weekly had a significantly longer median PFS than docetaxel-treated patients when assessed by both the independent radiologists (12.9 versus 7.5 months, respectively, p=0.0065) and the investigator (14.6 months versus 7.8 months, respectively, p=0.012) using RECIST guidelines. The overall response rate (ORR) tended to be higher with both weekly nab-paclitaxel regimens than docetaxel by independent radiology review. The investigator assessment found that the difference in ORR between both weekly nab- paclitaxel doses and docetaxel was statistically significant. Review by both the investigator and the independent radiologist found a significantly higher disease control rate (DCR) in patients receiving either dose of weekly nab-paclitaxel compared to docetaxel. All nab-paclitaxel doses showed an overall superior safety and toxicity profile over docetaxel. Dr. Gradishar said that the results of this study bolster earlier data identifying a role for nab-paclitaxel as a suitable option to docetaxel for first-line treatment of metastatic breast cancer. The study was sponsored by Abraxis BioScience, Inc. in Los Angeles, California. Written by Jill Stein Jill Stein is a Paris-based freelance medical writer. jillstein03(at)gmail.com Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009